Longeveron Stock News

These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.

A phase 2a study using Lomecel-B for Alzheimer's Disease is currently enrolling patients; a prior phase 1 study established excellent safety profile with some efficacy. The global Alzheimer's Disease

April events to highlight Longeveron's commitment to developing cell therapeutics for chronic aging related diseases. April events to highlight Longeveron's commitment to developing cell therapeutics

  Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer's Trial  This third collaboration with the Miami VA shows Longeveron's commitment to improving the health of our nation's Veterans. Miami, Florida - April 13, 2022 -- InvestorsHub NewsWire -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-th...

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech S

    Longeveron publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer's Disease in Alzheimer's & Dementia©: The Journal of the Alzheimer's Association Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality of Life for Alzheimer's Patients. Phase 2 Trial Recently Launched with First Patient Treated. Miami– March 31, 2022 - InvestorsHub NewsWire --&nb...

Longeveron (LGVN) stock is taking off on Thursday after the drugmaker published news related to an Alzheimer's treatment. The post Alzheimer's News: Why Is Drugmaker Longeveron (LGVN) Soaring Today?

Longeveron Inc (NASDAQ: LGVN) shares are trading higher Thursday after the company announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer's diseas

Energy is understandably at the top of every investor's mind right now, but finding the best energy stocks requires careful consideration. The post 5 Cheap Energy Stocks Riding Oil Higher appeared fir

There isn't just one kind of good stock, and there isn't just one good strategy for when to sell. You need a variety of approaches.

MIAMI, March 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related a

Longeveron Inc. (LGVN) CEO Geoff Green on Q4 2021 Results - Earnings Call Transcript

The clinical-stage biotechnology company Longeveron (LGVN) has lost ~10% in the pre-market Friday after the company signaled a potential delay for results from its Aging Frailty trial…